Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable